Two Sigma Securities, LLC Gilead Sciences, Inc. Put Options Transaction History

Two Sigma Securities, LLC

$5.78 Billion
Q3 2024

Put Options

28 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$66.59 - $83.99 $366,245 - $461,945	-5,500 Reduced 10.7%	45,900 $3.85 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $12,630 - $14,576	-200 Reduced 0.39%	51,400 $3.53 Million
Q1 2024 May 15, 2024	SELL	$71.58 - $87.29 $2.42 Million - $2.95 Million	-33,800 Reduced 39.58%	51,600 $3.78 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $718,046 - $814,282	-9,800 Reduced 10.29%	85,400 $6.92 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $2.58 Million - $2.82 Million	34,900 Added 57.88%	95,200 $7.13 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $2.99 Million - $3.42 Million	39,400 Added 188.52%	60,300 $4.65 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $1.34 Million - $1.52 Million	-17,300 Reduced 45.29%	20,900 $1.73 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $3.07 Million - $4.4 Million	-49,200 Reduced 56.29%	38,200 $3.28 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $6.46 Million - $7.38 Million	-108,500 Reduced 55.39%	87,400 $5.39 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $7.41 Million - $8.35 Million	128,400 Added 190.22%	195,900 $12.1 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $3.59 Million - $4.5 Million	62,000 Added 1127.27%	67,500 $4.01 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $155,712 - $176,736	-2,400 Reduced 30.38%	5,500 $399,000
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $2.88 Million - $3.11 Million	-42,600 Reduced 84.36%	7,900 $552,000
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $2.83 Million - $3.09 Million	44,600 Added 755.93%	50,500 $3.48 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $798,000 - $910,517	-13,300 Reduced 69.27%	5,900 $381,000
Q4 2020 Feb 16, 2021	BUY	$56.65 - $64.55 $413,545 - $471,215	7,300 Added 61.34%	19,200 $1.12 Million
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $304,290 - $382,592	-4,900 Reduced 29.17%	11,900 $752,000
Q2 2020 Sep 10, 2020	SELL	$72.34 - $84.0 $2.84 Million - $3.29 Million	-39,200 Reduced 70.0%	16,800 $1.29 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $8.69 Million - $11.1 Million	-138,700 Reduced 71.24%	56,000 $4.19 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $12 Million - $13.2 Million	194,700 New	194,700 $12.7 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $7.91 Million - $8.74 Million	-126,600 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $3.61 Million - $4.04 Million	58,300 Added 85.36%	126,600 $8.55 Million
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $243,867 - $273,195	-3,900 Reduced 5.4%	68,300 $4.44 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $11 Million - $14.4 Million	-182,100 Reduced 71.61%	72,200 $4.52 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $3.84 Million - $4.25 Million	-53,900 Reduced 17.49%	254,300 $19.6 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $5.83 Million - $6.8 Million	-89,900 Reduced 22.58%	308,200 $21.8 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $23.5 Million - $28.6 Million	322,400 Added 425.89%	398,100 $30 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $5.39 Million - $6.32 Million	75,700	75,700 $5.42 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$10.8 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.4 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$6.87 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.55 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.4 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.

Account